Chi-Med announced today that solepinib has been certified as an orphan drug by the US Food and Drug Administration to treat autoimmune hemolytic anemia. Solepinib is a novel, highly selective oral spleen tyrosine kinase inhibitor.

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.